ArticleBMC gastroenterology2026
Multi-omics analysis and experimental validation uncovers prognosis significance of IKBIP in patients with hepatocellular carcinoma: a multicenter cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundI Kappa B Kinase Interacting Protein (IKBIP) has been reported to promote tumor progression in diverse cancers. however, the role of IKBIP in hepatocellular carcinoma (HCC) has remained unclear.
methodsMulti-omics analysis was performed using data from publicly databases, to systematically assess the expression patterns, prognostic value and immune landscape of IKBIP in HCC. The prognostic value of IKBIP was further verified using immunohistochemical (IHC) examination in two independent clinical cohorts. Furthermore, human HCC cell lines (Huh7, MHCC-97 H and HepG2) were knocked down for IKBIP using small-interfering RNA (siRNA), and cell proliferation, and migration ability were assessed. RNA-sequencing was performed on Huh7 cells with IKBIP knockdown to explore the effect of IKBIP in HCC cells. A nomogram was constructed by combining IKBIP expression and clinicopathological parameters to predict prognosis for individual patient. Functional enrichment analysis was performed to identify key pathways associated with IKBIP. Immune infiltration analyses were conducted to explore the relationship between IKBIP expression and immune microenvironment.
resultsThe bioinformatics analyses indicated that IKBIP expression was significantly upregulated in tumor tissue and correlated with unfavorable prognosis. IHC experimental in both the Peking University Shenzhen Hospital (PKUSZ) and Shanghai Outdo cohorts demonstrated that IKBIP overexpression was associated with poorer survival. We found that IKBIP knockdown significantly inhibits HCC cell proliferation, colony formation, and migration in vitro. RNA-sequencing on IKBIP-knockdown Huh7 cells suggested that IKBIP played a role in promoting cell proliferation. The univariable and multivariable Cox analysis revealed that IKBIP expression was an independent factor for overall survival and diseases free survival. The nomogram by incorporating the IKBIP and clinicopathological features showed good performance in predicting prognosis. GSEA analysis revealed that IKBIP was associated with the cell cycle-related, epithelial-to-mesenchymal transition and angiogenesis pathways. We also found that IKBIP expression holds potential for predicting immunotherapeutic benefits.
conclusionsThe comprehensive multi-omics analysis and experimental findings demonstrate that IKBIP may be a biomarker with prognostic and functional significance in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.